GoMo Health Drives Participant Adherence and Real-World Data Capture in SHORE COPD Exacerbation Study with Strados Labs
Published on February 18, 2026
Published on
February 18, 2026
FOR IMMEDIATE RELEASE:
February 19, 2026
GoMo Health
Shelley Schoenfeld, Chief Marketing Officer
E-mail: sschoenfeld@gomohealth.com
Phone: 732-484-9144
Strados Labs
Gabe Steerman, Marketing Manager
E-mail: gabe@stradoslabs.com
Phone: 215-906-5538
Philadelphia, PA – February 19, 2026: GoMo Health is nurturing patient engagement and patient-reported outcomes (ePROs) in the SHORE (Study on Home Obstructive Respiratory Exacerbations) clinical research study led by Strados Labs in collaboration with Jefferson Einstein Philadelphia Hospital.
The SHORE study will enroll up to 20 adults following a chronic obstructive pulmonary disease (COPD) exacerbation and evaluate home-based recovery monitoring by combining continuous lung sound tracking using Strados Labs’ FDA-cleared RESP® Biosensor alongside structured daily patient-reported symptom data.
As part of the study, GoMo Health provides a digital engagement workflow that supports participant adherence and real-world data collection throughout recovery. After enrollment, participants receive personalized text prompts aligned to their routine, guiding completion of a brief respiratory questionnaire and entry of oxygen saturation readings. In this observational study, study teams are alerted only when expected responses are missed, enabling timely follow-up without continuous human outreach.
“Patient-reported outcomes remain a critical component of respiratory research, particularly in COPD, where symptoms and recovery can vary significantly after discharge,” said Bob Gold, Chief Behavioral Technologist, CEO and Founder, GoMo Health. “Our role in this study is to help ensure the patient voice is captured consistently and in context alongside physiologic monitoring, while making participation simple for individuals recovering at home.”
“COPD exacerbations remain a major driver of hospital readmissions and healthcare utilization,” said Devan Parson, Clinical Operations Manager, Strados Labs. “The SHORE study builds on our prior COPD research by evaluating how continuous, passive lung sound monitoring paired with structured home data collection can be implemented feasibly in patients’ everyday lives.”
This collaboration reflects a growing shift in clinical research toward combining objective digital biomarkers with patient-reported outcomes to better understand disease burden and treatment response. By pairing passive respiratory monitoring with daily symptom reporting, the study’s goal is to characterize recovery patterns following COPD exacerbations and inform future real-world respiratory disease research. Enrollment is currently underway.
About Strados Labs:
Strados Labs is a medical technology company focused on improving the lives of patients with respiratory diseases through innovative technology. The RESP® Platform enables real-world monitoring of lung health, including Strados Labs’ FDA-cleared RESP® Biosensor as well as watch-based wearables to capture respiratory symptoms in daily life.
By continuously capturing cough and lung sounds, the RESP® Platform provides clinicians with insight into respiratory status that may indicate exacerbations or changes in quality of life. The technology is also used by life sciences organizations to assess treatment effectiveness in clinical trials. Strados Labs is privately owned and based in Philadelphia, PA. For more information about Strados Labs and the SHORE study, visit stradoslabs.com.
About GoMo Health:
GoMo Health® delivers award-winning, evidence-based engagement solutions that improve health outcomes and reduce costs for providers, hospitals, health plans, employers, insurance, life science, and community health organizations. Our proprietary science, BehavioralRx®, applies proven behavioral and cognitive techniques—psychosocial, emotional, and physical— to address the whole person, building resilience and better supporting self-management, healthy decision-making, and sustained behavior change. Delivered through our cloud-based technology platform, GoMo Health programs are personalized, scalable, and automated, connecting participants to timely support and resources while enabling the collection of electronically reported outcomes to inform care and predictive modeling. In 2025, GoMo Health achieved HITRUST Risk-based (r2) Certification, the most rigorous certification in the HITRUST portfolio, for its Personal Concierge and GoMo Chat products on Microsoft Azure.
To learn more, visit www.gomohealth.com.
